Toxicity
In both groups 24% of patients discontinued due to toxicity (adverse event or cardiac toxicity). In the liposomal doxorubicin group 22% discontinued due to an adverse event and 2.4% due to cardiac toxicity, whereas among the doxorubicin group 9.4% discontinued due to an adverse event and 14% due to cardiac toxicity. Palmar-plantar erythrodysesthesia (PPE) was the most common adverse event 48% (grade 3 = 17%) with the liposomal doxorubicin group.r
Treatment-related adverse eventsr
© Annals of Oncology 2004
Cardiac toxicity during treatment and follow-upr
© Annals of Oncology 2004
Cardiac toxicity related to cumulative dose of anthracycliner
© Annals of Oncology 2004